Macrogenics, Inc.
$8.2M 16 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Epizyme, Inc.
Epizyme, Inc. reported $8,122,556.33 across General Payments, Research, and Ownership to 46 physicians and teaching hospitals across 2,516 transactions.
- $8.1M Top quartile payer
- All-tracks total
- 2,516 Top quartile volume
- Transactions
- 46 Below-median reach
- Recipients
- −$23.8K
- General Payments vs PY2023
Epizyme, Inc. reported $8,122,556.33 across all CMS Open Payments tracks (General + Research + Ownership) to 46 physicians and teaching hospitals in Program Year 2024 - ranking #207 of 1,925 reporting manufacturers (0.1% of the all-tracks industry total); General Payments alone were $16,395.29, averaging $176.6K per recipient.
How Epizyme, Inc.'s $8.1M all-tracks total breaks down
Epizyme, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
37/100
Total payments
B
85/100
Transaction volume
F
28/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer epizyme-inc Epizyme, Inc.
$8.1M · #207/1,925 · 0.1% industry · PY2024
- TOT $8.1M
- RANK #207
- SHARE 0.1%
- TXN 2,516
- RCP 46
- CAT 2
- GEN $16.4K
- ΔGEN −$23.8K
- TOP1 54.9%
- PY 2024
Volume peers
Nearest volume peer: Macrogenics, Inc. ($8.2M)
Epizyme, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Epizyme, Inc.'s CMS-reported General Payments decreased by $23.8K (−59.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EPIZYME, INC.PY2023: EPIZYME, INC.PY2024: Epizyme, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $40,157.11
- PY2024
- $16,395.29
What the Data Shows for Epizyme, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Epizyme, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
7 transactions worth $15.4K make "Consulting Fee" the top general-payment category in the 2-category breakdown below, 93.8% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Consulting Fee" leads Epizyme, Inc.'s 2-category general-payment breakdown at $15.4K, 93.8% of the reported total.
How Epizyme, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $15.4K | 7 | 93.8% |
| Food and Beverage | $1.0K | 39 | 6.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $15,504.82 (94.6%) of $16,395.29 in this company's General Payments records across 43 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Epizyme, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Azra Raza
$9,000.00 across 1 reported transactions
- 2
Rafael Bejar
$3,600.00 across 2 reported transactions
- 3
Susan M O Brien
$1,500.00 across 2 reported transactions
- 4
Richard a Larson
$1,275.00 across 2 reported transactions
- 5
Michael a Morse
$129.82 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Epizyme, Inc.'s spend rank (#207 of 1,925, top 11% by spend) and concentration rank (#485 of 1,838, top 26% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Pristine Surgical LLC : $19.0K total payments, HHI 3684
- Circle Cardiovascular Imaging Inc. : $14.6K total payments, HHI 3678
- Merakris Therapeutics, Inc. : $10.4K total payments, HHI 3674
- aap Implants Inc : $631.69 total payments, HHI 3671
- Polarean, Inc. : $131.4K total payments, HHI 3654
- AccuTec Blades Inc : $45.1K total payments, HHI 3645
- Epizyme, Inc. (this company) : $16.4K total payments, HHI 3641
- OrphAI Therapeutics Inc. : $24.4K total payments, HHI 3624
- Flume Catheter Company Inc. : $15.0K total payments, HHI 3600
- Skeletal Dynamics Inc : $2.8M total payments, HHI 3598
- CooperSurgical, Inc. : $1.9M total payments, HHI 3590
- Medicines360 : $319.8K total payments, HHI 3588
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Epizyme, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Epizyme, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Epizyme, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Rhythm Pharmaceuticals, Inc.
$8.1M 1,007 recipients
Compare payment profiles
Applied Medical Corporation
$8.0M 5 recipients
Compare payment profiles
Lightforce Orthodontics, Inc.
$8.3M 2,676 recipients
Compare payment profiles
Optimotion Implants, LLC
$8.0M 6 recipients
Compare payment profiles
Beckman Coulter, Inc.
$8.3M 469 recipients
Compare payment profiles
Put this to use
Epizyme, Inc. ranks #207 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Epizyme, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Epizyme, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.